---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-22-000016"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T12:00:21.470131+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed

## Summary
- Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).
- Full-year revenue $28,318.4M (+15%); non-GAAP EPS $8.16 (+20%).
- COVID-19 antibody revenue $1.06B in Q4, $2.24B for full year.
- Key growth products (Trulicity, Taltz, Verzenio, Jardiance, Olumiant) contributed 14 ppt revenue growth ex-COVID.
- 2022 EPS guidance: GAAP $8.00-$8.15, non-GAAP $8.50-$8.65; dividend raised 15%.

## SEC filing metadata
- accession: 0000059478-22-000016
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/0000059478-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/lly-20220203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-22-000016
- JSON: https://secwatch.observer/filing/0000059478-22-000016.json
- Plain text: https://secwatch.observer/filing/0000059478-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.